Tuberous sclerosis (TSC [MIM 191090 and MIM 191100]) is an autosomal dominant disorder characterized by hamartomas in many organs. Two thirds of cases are sporadic and are thought to represent new mutations. TSC is caused by mutations affecting either of the presumed tumor-suppressor genes, TSC1 and TSC2. Both appear to function as tumor suppressors, because somatic loss or intragenic mutation of the corresponding wild-type allele is seen in the associated hamartomas. Here we report the first comprehensive mutation analysis of TSC1 and TSC2 in a cohort of 150 unrelated TSC patients and their families, using heteroduplex and SSCP analysis of all coding exons and using pulsed-field gel electrophoresis and conventional Southern blot analysis and long PCR to screen for large rearrangements. Mutations were characterized in 120 (80%) of the 150 cases, affecting TSC1 in 22 cases and TSC2 in 98 cases. TSC1 mutations were significantly underrepresented in sporadic cases ( ). Twenty-two patients had P ϭ .000185 TSC2 missense mutations that were found predominantly in the GAP-related domain (eight cases) and in a small region encoded in exons 16 and 17, between nucleotides 1849 and 1859 (eight cases), consistent with the presence of residues performing key functions at these sites. In contrast, all TSC1 mutations were predicted to be truncating, consistent with a structural or adapter role for the encoded protein. Intellectual disability was significantly more frequent in TSC2 sporadic cases than in TSC1 sporadic cases ( ). These P ϭ .0145 data provide the first representative picture of the distribution and spectrum of mutations across the TSC1 and TSC2 loci in clinically ascertained TSC and support a difference in severity of TSC1-and TSC2-associated disease.
Introduction
Tuberous sclerosis (TSC [MIM 191090 and MIM 191100] ) is a disorder characterized by hamartomatous involvement of many organs (Gomez 1988) and is estimated to affect у1/10,000 live births (Osborne et al. 1991) . It is inherited as an autosomal dominant trait, but 60%-70% of cases are sporadic and are thought to represent new mutations (Fleury et al. 1980; Sampson et al. 1989 ). The phenotype is highly variable. The brain, skin, kidneys, and heart are all involved frequently, the lungs, skeleton, endocrine glands, and most other organs occasionally (Gomez 1988) . Traditional diagnosis has been based on combinations of clinical, radiological, and histopathological signs; the criteria for definite diagnosis have been revised recently and have become more stringent than before ). Significant and common medical complications include epilepsy (75%), intellectual disability (50%), and behavioral problems (including autism and attention-deficit disorder with hyperactivity, in 40% of children). Penetrance is very high, and the only cases of apparent nonpenetrance reported after rigorous clinical evaluation have been recently disproved by molecular genetic analysis (Young et al. 1998) .
Two TSC-determining genes have been identified by positional cloning-TSC1 at 9q34 (van Slegtenhorst et al. 1997 ) and TSC2 at 16p13.3 (European Chromosome 16 Tuberous Sclerosis Consortium 1993). Molecular genetic analysis of hamartomatous and occasional malignant growths from patients with tuberous sclerosis have revealed loss of heterozygosity or truncating intragenic mutations affecting the corresponding wild-type allele (Henske et al. 1996; Sepp et al. 1996; van Slegtenhorst et al. 1997) , indicating that TSC1 and TSC2 act as tumor suppressors, as defined by Knudson (1971) . The tumorsuppressing properties of TSC2 have now been demonstrated directly by transgenic expression in the Eker rat, a naturally occurring model in which the homologous Tsc2 gene is mutated (Kobayashi et al. 1997) . The mechanisms through which TSC1 and TSC2 mediate cellular growth control have been only partially elucidated. Exons 34-38 of TSC2 encode a GTPase-activat-ing protein (GAP)-related domain having significant homology to the GAPs rap1GAP and murine Spa1 . Tuberin, the TSC2 product, possesses modest GAP activity for rap1 (Wienecke et al. 1995) and rab5 (Xiao et al. 1997) . These members of the Ras superfamily of GTPases serve roles in mitogenesis (Altschuler and Ribeiro Neto 1998) , neuronal differentiation (York et al. 1998) , and early endosome fusion (Gorvel et al. 1991) . Tuberin also appears to play a role both in cyclin-dependent kinase (CDK)-dependent regulation of transition from G 0 /G 1 to S phase during the cell cycle (Soucek et al. 1997 ) and in neuronal differentiation (Soucek et al. 1998) . Specific cellular roles have not yet been reported for hamartin, the TSC1 product, but hamartin and tuberin have been shown to coimmunoprecipitate, interact in the yeast two-hybrid system, and colocalize on immunofluorescence (Plank et al. 1998; van Slegtenhorst et al. 1998) , suggesting that the proteins participate in at least some common pathways.
Mutation analysis of both TSC1 and TSC2 has not been reported previously in a series of patients with TSC. Comprehensive analysis of TSC2 has been frustrated both by the size and structure of the gene (i.e., 41 coding exons and 1 leader exon) and because, until very recently, the full genomic sequence has not been available. There are several reports of single or small numbers of TSC2 mutations identified during incomplete screening of the gene (Kumar et al. 1995a (Kumar et al. , 1995b (Kumar et al. , 1997 Vrtel et al. 1996; Jobert et al. 1997; Verhoef et al. 1998; Wang et al. 1998) . Three studies have attempted more complete analysis of TSC2. Wilson et al. (1996) have used single-strand conformation polymorphism (SSCP) analysis of reverse-transcriptase-PCR products to study 30 unrelated probands and have reported nine possible mutations. One mutation, DF1509, has subsequently been seen in unaffected controls and is believed to be nonpathogenic . The pathogenicity of several missense changes identified in that study remains unconfirmed. van Bakel et al. (1997) have used the protein-truncation test to study 18 unrelated patients and have identified truncating mutations in 5 of them. Au et al. (1998) have used SSCP analysis of all coding exons to study 90 unrelated cases and have identified 22 putative mutations. In addition, several studies have been made of patients with TSC and severe polycystic kidney disease, most of whom appear to have a contiguous gene-deletion syndrome involving TSC2 and the adjacent autosomal dominant polycystic kidney disease type 1 gene, PKD1 (Brook-Carter et al. 1994; Longa et al. 1997; Sampson et al. 1997) . Analysis of the TSC1 gene has proved more straightforward. The complete genomic sequence of TSC1 was established when the gene was identified. It is significantly less complex than TSC2, comprising 21 coding and 2 leader exons. At least five systematic studies of TSC1 mutations have been reported Ali et al. 1998; Kwiatkowska et al. 1998; Young et al. 1998; in press); all identified TSC1 mutations in only 10% of sporadic cases of TSC. It is therefore clear that previous studies of TSC have failed to identify most of the causative mutations.
We set out to determine the distribution and nature of TSC1 and TSC2 mutations in a large and representative series of patients and families with TSC. Knowledge of these parameters is required both for development of efficient molecular diagnosis and for studies of the genotype-phenotype relationship. In previous studies of this patient cohort, we have screened all coding exons of the TSC1 gene and exons 1, 25, 31, 34-39, and 41 of the TSC2 gene, and we have searched for large-scale rearrangements at the TSC1 and TSC2 loci Maheshwar et al. 1997) . To obtain comprehensive data, we have completed SSCP and heteroduplex analysis of all TSC2 exons and, by means of Southern analysis and long PCR, have supplemented our previous search for large rearrangements at both loci.
Patients and Methods

Patients
The study was approved by the ethics committee of the Division of Medicine, South Glamorgan Health Authority. The index cases comprised 150 consecutive unrelated patients with TSC who were listed with the Institute of Medical Genetics, Cardiff, prior to April 1994 and for whom samples were available for comprehensive analysis of the TSC1 and TSC2 genes. Patients specifically ascertained by us for a separate study of renal cystic disease in TSC were not included, but nine cases ascertained for other reasons who were subsequently found to have polycystic kidneys were included. Initially the series comprised 171 apparently unrelated patients, but 21 were excluded, 7 because they failed to satisfy the recently revised criteria for diagnosis of definite TSC , 13 because further samples required for completion of the analysis were not available, and, in 1 case, because previously unrecognized kinship to another index case who carried the same mutation was identified. Intellectual disability was considered to be present when formal developmental assessment revealed a developmental quotient!70, when unassisted mainstream schooling was impossible because of intellectual disability (not behavioral problems), or when an adult was institutionalized or required supervision in the community.
PCR
Genomic DNA was prepared from peripheral blood samples by standard methods. PCR primers were de-signed with the aid of the "Oligo Analysis" software package (Wojciech Rychlik). Primer sequences and annealing temperatures for amplification of all TSC1 and TSC2 coding exons and for long PCR at the TSC1 and TSC2 loci are available at the Cardiff-Rotterdam Tuberous Sclerosis Mutation Database Website. Standard PCR was done in 50-ml reaction volumes containing 100 ng of genomic DNA, 25 pmol of each primer, 0.2 mM dNTP, 5 ml of reaction buffer (100 mM Tris pH 8.3, 500 mM KCl, 15 mM MgCl 2 , 0.01% gelatin), and 1 U of AmpliTaq Gold Polymerase (Cetus). Cycling parameters were 94ЊC for 10 min, followed by 32 or 33 cycles of 54ЊC-58ЊC for 1 min, 72ЊC for 1 min, and 94ЊC for 30 s, and a final step of 72ЊC for 10 min. Long PCR was done in 50-ml reaction volumes containing 100 ng of genomic DNA, 4 pmol of each primer, 0.35 mM dNTP, 5 ml of Boehringer-Mannheim reaction buffer 3 (20 mM Tris -HCl, 100 mM KCl, 22.5 mM MgCl 2 , 1 mM DTT, 0.1 mM EDTA, 0.5% [v/v] 
SSCP and Heteroduplex Analysis
SSCP was done on 3 ml of PCR product diluted 1:10 with formaldehyde containing 0.0125% bromophenol blue and 0.75% Ficoll 400. Samples were denatured at 94ЊC for 5 min, snap-cooled on ice, and triple-loaded (at 2-h intervals) on a mutation detection enhancement (MDE) gel (Flowgen). Electrophoresis was done in borate EDTA at 6 W for 18 h at room tem-0.6 # Tris perature. Heteroduplex analysis was performed by mixing of 5-ml aliquots of two PCR products with 0.6 ml of 0.1 M EDTA, denaturing at 94ЊC for 5 min, and then slow cooling to 37ЊC. One microliter of electrophoresis dye (Hoefer) was added to each of the samples, which were then quadruple-loaded (at 1-h intervals) on an MDE gel and run at 4.5 W for 15 h at room temperature. Products on SSCP and heteroduplex gels were visualized by silver staining, as described elsewhere .
DNA Sequencing
PCR products of samples displaying variant banding patterns were sequenced by means of either the Sequenase PCR Product Sequencing kit or the ThermoSequenase cycle sequencing kit (Amersham).
Southern Analysis
Genomic DNA for Southern analysis was digested with EcoRI, HindIII, and BamHI, electrophoresed, and blotted, as described elsewhere , and were probed with TSC1 and TSC2 cDNA clones. Samples yielding variant restriction patterns were subjected to further restriction analysis to characterize the mutations involved. Products generated by long PCR amplification were blotted to Hybond N ϩ . Amplified exons were used as probes to determine which were deleted and which were preserved on the mutant chromosomes.
Microsatellite Analysis
Evidence for biological paternity and maternity in cases with apparently de novo mutations was assessed by means of highly polymorphic microsatellite repeats on chromosomes 4 (D4S43), 6 (D6S250), 7 (D7S636), 15 (D15S945), and 16 (D16S665).
Mutation Nomenclature
Mutation nomenclature has been inconsistent at the TSC2 locus, since the transcript initially reported by the European Chromosome 16 Tuberous Sclerosis Consortium (1993) did not contain the nucleotides corresponding to exon 31, which is subject to alternative splicing . We numbered nucleotides according to the full-length TSC1 and TSC2 cDNAs as in GenBank (accession numbers AF013168 and X75621, respectively), and mutations were described as recommended by the Ad Hoc Committee on Mutation Nomenclature (1996) .
Results
Sample Characteristics
Of the 150 index cases comprehensively screened for TSC1 and TSC2 mutations, 130 were sporadic, 19 were classified as familial (having an affected parent, with or without other affected family members), and 1 patient had been adopted and the clinical status of the biological parents was unknown. At ascertainment, the total number of living affected individuals in the 150 families was 199, and the overall proportions of sporadic and familial cases were 65% and 35%, respectively. Thirteen further cases were screened by pulsed-field gel electrophoresis (PFGE) and by SSCP and heteroduplex analysis of coding exons of TSC1 but, because of inadequate or degraded DNA samples, were not screened comprehensively for mutations of TSC2.
Mutations at the TSC Loci
Likely disease-causing mutations were characterized in 120 (80%) of the 150 index cases; of these 120 mutations, 22 (18%) were at the TSC1 locus, and 98 (82%) were at the TSC2 locus. In a previous study, we had reported all but one of the TSC1 mutations (Jones et al. Jobert et al. (1997) . b Also observed in a patient reported by Wilson et al. (1996) . c Also reported by Maheshwar et al. (1997) . d Also reported by Jones et al. (1997). 1997). In that study, patient 365 with sporadic TSC was shown to have the de novo TSC1 missense mutation A726E. We have now also demonstrated a de novo TSC1 nonsense mutation W750X, Gr A at 2471, in this patient. The presence of both de novo mutations was confirmed through repeat samples, and biological parenthood was confirmed through five polymorphic microsatellite markers. The TSC2 mutations are summarized in tables 1-3. With regard to the TSC2 locus, 22 patients had whole-exon, multiexon, or whole-gene deletions or other large rearrangements, 20 had nonsense changes, 21 had small insertions or deletions predicted to lead to both a change of reading frame and premature truncation, 8 had changes in splice-site consensus sequences, 5 had in-frame deletions of one to six aminoacid residues, and 22 had missense changes. Evidence for pathogenicity of the TSC2 missense changes and small in-frame deletions was obtained by study of additional family members. Two small in-frame deletions-DI365 (unique) and 5256del18bp (recurrent)-were shown to arise de novo in sporadic cases, as were 11 of 14 different missense mutations. In all these cases, results of analysis of five polymorphic microsatellite markers were consistent with biological parenthood. A further unique missense change, G294E, occurred in a familial case; its pathogenicity is unconfirmed. Segregation of the missense change with TSC in this family has been demonstrated by others (A. Astrinidis and S. Povey, personal communication). Parental samples were unavailable for two apparently sporadic cases, 050 and 253, who carried the unique missense changes C696Y and R1743P and in whom no other TSC1 or TSC2 mutations were identified. The missense mutations were located principally in the GAP-related domain of TSC2 encoded in exons 34-38 and in a short stretch of nucleotides at positions 1849-1859 (table 2  and fig. 1 ). Small truncating lesions were distributed across the TSC1 and TSC2 genes ( fig. 1) .
Eight TSC2 mutations (tables 1 and 2) and one TSC1 mutation, CrT at 2577, R786X, were seen recurrently. Together, these accounted for 28 (23%) of the 120 mutations identified (i.e., 19% of the 150 index cases).
TSC1 and TSC2 Mutations in Familial and Sporadic Cases
Of the 19 familial cases, 9 had TSC1 mutations and 9 had TSC2 mutations; no mutation was detected in 1 (5%) of the familial cases. Of the 130 sporadic cases, 13 had TSC1 mutations and 88 had TSC2 mutations; no mutation was detected in 29 (22%) of the sporadic cases. TSC1 mutations were therefore significantly underrepresented among sporadic cases ( , 1 df; 2 x ϭ 13.975 ). One adopted case with an unknown fam-P ϭ .000185 ily history had a TSC2 mutation.
Germ-Line Mosaicism
In 1 of the 150 families studied, two affected siblings had parents who were normal on clinical examination. The TSC2 mutation R905W (CrT at 2731) was iden- Wilson et al. (1996) b Also reported by Au et al. (1998) c Also reported by Maheshwar et al. (1997) .
tified in the index case, patient 362, and in his affected sibling but was not detected in DNA extracted from leukocytes from each of the parents. Result of analysis of five microsatellite markers were consistent with biological parenthood, suggesting the presence, in one of the parents, of mosaicism involving the germ line for this mutation.
Polymorphisms
Thirty-nine sequence variants likely to represent nonpathogenic polymorphisms were observed at the TSC2 locus, both in TSC patients and in either normal controls or TSC-family members without clinical or radiographic evidence of TSC. Thirty of these have not been reported previously unreported and are listed in table 4; they include nine missense variants within the coding region. TSC1 polymorphisms have been reported elsewhere .
Intellectual Disability
Intellectual disability was present in 86 (57%) of the 150 index cases and in 97 (49%) 
Unusual Somatic Features
Gross polycystic kidney disease was detected on ultrasound scan (but was not the presenting feature) in nine cases. All of these cases had TSC2 mutations, and, in six cases, these mutations were contiguous deletions also involving the PKD1 gene. Four of the six cases with TSC2/PKD1 deletions were somatic mosaics. Two cases had large intragenic deletions affecting TSC2, and one case had a 600-kb inversion disrupting TSC2 (table 3). All cases have been reported elsewhere (European Chromosome 16 Tuberous Sclerosis Consortium 1993; Brook-Carter et al. 1994; Sampson et al. 1997) . Fifteen of 22 index cases with TSC1 mutations had no evidence Inversion ≈600 kb PFGE Sampson et al. (1997) of renal cysts on ultrasound scan. Three had unilateral solitary cysts (at age 35, 50, and 64 years). No renal ultrasound scan was performed in four cases with TSC1 mutations. Three female patients had a history of pneumothorax and either cystic or honeycomb changes in the lungs on radiographic investigation, consistent with a diagnosis of lymphangioleiomyomatosis (LAM). One case, patient 080, had a large deletion mutation involving both the 5 end of TSC2 and the OCTS3 and OCTS2 genes, which lie immediately 5 of TSC2. Another case, patient 208, had the recurrent TSC2 missense change R611W. The third case, patient 256, had bony sclerosis, with expansion of the right clavicle, and asymmetry affecting the right side of the face, in addition to cystic changes in the right lung. This patient carried the TSC1 nonsense change S334X. All of these cases were sporadic.
Localized overgrowth affecting the limbs was observed in three female patients, all of whom otherwise had typical multiorgan involvement. TSC2 mutations were identified in DNA extracted from venous blood in two of these patients. Patient 211, carrying the de novo missense change S1498N, had massive overgrowth of the right leg, involving the bones and soft tissues, that progressed during infancy and childhood and that, at age 30 years, led to amputation of the leg. Patient 046 carried the single-base deletion 546delC and had overgrowth localized to the left little finger. No mutation was identified in the third case, who had overgrowth affecting the bones and soft tissues of the left forearm and of the middle and ring fingers.
Discussion
We studied 150 unrelated individuals with TSC, as well as their family members. The proportions of familial and sporadic cases among all 199 affected members of their families were 35% and 65%, respectively, and the overall frequency of intellectual disability was 49%. These figures are similar to those reported in large epidemiological studies (Sampson et al. 1989; Osborne et al. 1991) , suggesting that the present series is representative of clinically ascertained TSC. We identified mutations in a total of 120 (80%) of these patients; 98 (65.4%) were shown to have mutations at the TSC2 locus, and 22 (14.6%) had mutations at the TSC1 locus. One hundred one different mutations were characterized (21 affecting TSC1 and 80 affecting TSC2), of which 42 had not been described previously. Mutations were not identified in 1 of 19 familial cases or in 29 of 130 sporadic cases. Recent studies have shown that somatic mosaicism may be a frequent finding among sporadic cases of TSC . The SSCP and heteroduplex analyses used for exon screening in this study are unlikely to have had sufficient sensitivity to detect low-level mosaicism, and they also have limited sensitivity in the detection of some nonmosaic mutations. These factors, as well as our incomplete assessment of intronic and regulatory sequences, likely account for our failure to detect mutations in 20% of the cases. Further locus heterogeneity in TSC also remains a theoretical possibility. We found that significantly more of the sporadic cases had TSC2 than had TSC1 mutations. This would be expected if the germ-line mutation rate at the TSC2 locus were higher than at the TSC1 locus. However, additional familial TSC2 cases would also be expected, and we did not observe this; nor has a significant excess of families without linkage to TSC1 been observed in linkage studies (Sampson et al. 1991; Povey et al. 1994) . A possible explanation for the apparent excess of TSC2 mutations among sporadic cases-but not among familial caseswould be greater overall severity of TSC2-associated disease. We assessed the frequency of intellectual disability in sporadic cases, as a reliable and important aspect of disease severity. Unlike many other components of the phenotype that show age-dependent penetrance, intellectual disability in TSC is almost invariably present from early childhood and rarely escapes detection. We found intellectual disability to be significantly more frequent among sporadic cases with TSC2 mutations than among those with TSC1 mutations. If the presence or absence of intellectual disability is, in part, related to the frequency of "second hit" mutations in the developing brain, then our observations could reflect a somatic mutation rate that is higher at the TSC2 locus than at the TSC1 locus. Alternatively, tuberin may serve roles in the CNS that are not shared by hamartin.
Elsewhere, we have shown that most patients with TSC and severe polycystic kidney disease have contiguous deletions involving TSC2 and the adjacent polycystic kidney disease 1 (PKD1) gene (Brook-Carter et al. 1994; Sampson et al. 1997 ). The present series did not include cases specifically ascertained because of polycystic kidney disease, but polycystic kidney disease was identified in 9 of the 150 index cases. Six of these cases had TSC2-PKD1 deletions, of whom four were mosaics. Deletion of TSC2 and of only the 3 UTR of PKD1 was found in a further case, who did not have polycystic kidneys. Three cases with polycystic kidneys had TSC2 mutations that did not involve PKD1. Solitary cystsbut not polycystic kidneys-were seen in some patients with TSC1 mutations. Specific study of a larger cohort of patients is required in order to determine whether TSC1 disease carries a risk of clinically significant renal cystic disease.
Symptomatic cystic lung disease presenting as pneumothorax was a feature in three cases in the present series. Two patients with TSC2 mutations had widespread honeycomb appearances in both lungs that was typical of LAM, and the third, with a TSC1 mutation, had marked cystic changes in the upper lobe of the right lung. LAM is a disorder seen almost exclusively in females and is characterized by bronchiolar smooth-muscle infiltration and cystic changes in the lung parenchyma. This is usually associated with angiomyolipoma of the kidneys and/or abdominal and hilar lymph nodes. Symptomatic LAM is estimated to occur in ∼1/million of the population, without other evidence of TSC, but in several percent of females with TSC, implicating a role for the TSC genes in the etiology of LAM. Loss of heterozygosity for markers in the TSC2 region has been observed in renal angiomyolipomas and lymph nodes removed from women with LAM but without other signs of TSC (Smolarek et al. 1998 ), but mutations of the TSC genes had not been reported previously in patients with either TSC-associated LAM or sporadic LAM.
Studies of other components of the TSC phenotype in TSC1-and TSC2-associated disease are now required, particularly to quantify the frequency and severity of complications. Given our findings in relation to the distribution of TSC1 and TSC2 mutations in sporadic and familial cases, as well as the likelihood that familial cases will be less severely affected than are sporadic cases, such studies will have to be based on either sporadic cases or epidemiologically complete populations, or they will have to employ valid corrections for ascertainment bias.
The large proportion of TSC2 mutations-as opposed to TSC1 mutations-that we observed in medically ascertained TSC has implications for the development of molecular diagnostics. Not only is the TSC2 gene, in its structure, substantially more complex than the TSC1 gene, but we have also found its mutational spectrum to be more diverse. Several studies have found the great majority of germ-line mutations at the TSC1 locus to be small truncating lesions Ali et al. 1998; Kwiatkowska et al. 1998; Young et al. 1998; van Slegtenhorst et al., in press ). In contrast, we have now shown that, at the TSC2 locus, missense changes, large rearrangements including whole-gene deletions, nonsense mutations, and small insertions and deletions are represented at similar frequencies. The sensitivity of any single currently available approach for mutation detection at the TSC2 locus is therefore likely to be limited. However, we did observe eight TSC2 mutations recurrently, at least three of which (R505X, R611W, and R611Q) have also been reported by other investigators (Wilson et al. 1996; van den Ouweland et al. 1997; Au et al. 1998) . Seven of the mutations seen recurrently were due to CrT or GrA substitutions at CpG dinucleotides and are likely to result from spontaneous deamination of methylated cytosines in the genomic DNA. The inframe TSC2 deletion, 5256del18bp, was identified in four unrelated sporadic cases. It involves a direct repeat of 11 nucleotides and the intervening 7 nucleotides and is likely to be the result of slipped mispairing during replication (Cooper and Krawczak 1993) . Several TSC1 mutations also have been seen recurrently van Slegthenhorst et al. 1997, and in press; Ali et al. 1998; Kwiatkowska et al. 1998; Young et al. 1998) , suggesting that assay for a small number of TSC2 and TSC1 mutations might provide a useful initial screen in the diagnostic setting.
Our characterization of significant numbers of missense mutations and some small in-frame deletions at the TSC2 locus is likely to be helpful in the investigation of putative functions of the gene product. The effects that the missense changes in the GAP-related domain have on GAP activity toward rap1 and rab5 are now under investigation, as is the effect that the single-residue deletion DI365 has on the binding of hamartin by tuberin. Natural mutants of this kind may prove useful for determination of which of tuberin's functions has a requirement for hamartin binding. The recurrent 18-p deletion in exon 40 of TSC2 lies within the putative rabaptin-binding domain (Xiao et al. 1997) . However, demonstration of the binding of rabaptin by tuberin awaits independent confirmation, and the pathogenic mechanism of this mutation is unclear at present. We and others (Wilson et al. 1996; van den Ouweland et al. 1997; Au et al. 1998 ) have identified recurrent missense mutations within a short stretch of only 11 nucleotides (1849-1859) of TSC2. This region does not correspond to any currently recognized functional domain of tuberin, but the effects that these mutations have on recently proposed roles of tuberin, including regulation of G 0 /G 1 to S phase transition (Soucek et al. 1997) , can now be assessed. In contrast, despite reports of large numbers of single-base changes and small deletions and insertions at the TSC1 locus, no clearly pathogenic missense mutations have been described, and it appears likely that complete loss of hamartin-rather than moresubtle disruption of specific roles-is usual in TSC1 associated disease.
Note added in proof.-Since this article was accepted for publication, mutations have been identified in three further sporadic cases, all at the TSC2 locus. These were (i) an intragenic deletion of ∼5 kb in patient 165 (identified by long PCR), (ii) a deletion of 34 bp from a 34-bp tandem repeat spanning the exon 38/intron 38 boundary in patient 112 (the same mutation has been reported elsewhere, in a different patient with TSC [Beauchamp et al. 1998 ]), and (iii) a deletion of exon 41 and the 3 UTR of TSC2 and part of the 3 UTR of PKD1 in patient 115 (identified by long PCR).
